Systemic Aspergillosis And Systemic Candidiasis Market Growth Through 2030 Creates New Strategic Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Systemic Aspergillosis And Systemic Candidiasis Market Forecast: What Market Value Is Expected By 2030?
In recent times, the market encompassing systemic aspergillosis and candidiasis has experienced consistent expansion, projected to increase from $7.57 billion in 2025 to $7.94 billion in 2026, reflecting a compound annual growth rate of 4.9%. This upward trend during the past period is largely attributable to a growing number of patients with weakened immune systems, a higher incidence of invasive fungal infections, the accessibility of both azole and amphotericin treatments, the enlargement of hospital intensive care facilities, and enhanced understanding and recognition of diagnostic methods for these conditions.
The market for treating invasive aspergillosis and invasive candidiasis is projected for significant expansion in the coming years, reaching an estimated $9.76 billion by 2030, fueled by a compound annual growth rate of 5.3%. This anticipated growth trajectory is underpinned by several key drivers, including the ongoing development of innovative antifungal medications, a heightened emphasis on strategies to combat antifungal resistance, the broader application of specialized antifungal treatments, escalating investments in research concerning infectious diseases, and a growing inclination toward employing combined treatment strategies. Furthermore, the forecast period is expected to be characterized by significant trends such as the increased utilization of sophisticated antifungal therapies, a greater focus on the prompt identification of systemic fungal infections, the proliferation of combined approaches to antifungal therapy, a surge in demand for antifungals used in critical hospital care settings, and improved surveillance of drug resistance trends.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp
Systemic Aspergillosis And Systemic Candidiasis Market Growth Drivers: What Factors Are Accelerating Expansion?
The rising prevalence of fungal infections is anticipated to be a significant catalyst for the expansion of the market for systemic aspergillosis and systemic candidiasis. Fungal diseases encompass a broad spectrum of ailments caused by fungi, capable of impacting diverse bodily regions and leading to a variety of symptoms and adverse outcomes. These infections range from superficial skin afflictions and respiratory issues to deep-seated systemic invasions. Treatment for these conditions typically involves antifungal agents, including oral azoles, voriconazole, and liposomal amphotericin B. Illustrating this trend, data from the UK Health Security Agency revealed that in 2023, England experienced a 4% increase in bloodstream infections attributed to yeast compared to the preceding year. Consequently, the escalating occurrences of fungal diseases are directly fueling the development of the systemic aspergillosis and systemic candidiasis market.
Systemic Aspergillosis And Systemic Candidiasis Market Segment Analysis: What Are The Major Market Categories?
The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –
1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users
Subsegments:
1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole
2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection
3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis
4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines
5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents
Systemic Aspergillosis And Systemic Candidiasis Market Trends: What Is Shaping Future Industry Growth?
Leading players within the systemic aspergillosis and systemic candidiasis sectors are prioritizing the creation of cutting-edge therapies, including echinocandins, aiming to boost treatment success rates and combat the increasing problem of antifungal resistance. Echinocandins function by disrupting the production of ß-glucan, a vital element of the fungal cell’s outer layer. Illustrating this progress, in March of 2023, Cidara Therapeutics and Melinta Therapeutics, both American biotechnology firms, secured approval from the U.S. Food and Drug Administration for REZZAYO, an injectable form of rezafungin. This new, once-weekly echinocandin formulation is intended for treating candidemia in adult patients who have exhausted or have no other viable treatment alternatives. REZZAYO’s design, emphasizing a simplified once-weekly administration schedule, facilitates treatment adherence and ensures uninterrupted care for individuals suffering from invasive candidiasis, offering significant advantages particularly in hospital environments where prompt and effective management of these serious infections is paramount.
Systemic Aspergillosis And Systemic Candidiasis Market Leading Companies Driving Competitive Growth
Major companies operating in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline PLC, Gilead Sciences Inc, Astellas Pharma Inc, Matinas BioPharma Holdings Inc, Shionogi & Co. Ltd, Cipla Limited, Basilea Pharmaceutica Ltd, Cidara Therapeutics Inc, Entasis Therapeutics Inc, F2G Ltd, Mycovia Pharmaceuticals Inc, ContraFect Corporation, Enzon Pharmaceutical Inc, Pacgen Life Science Corporation, Biosergen AS
Access The Complete Systemic Aspergillosis And Systemic Candidiasis Market Report:
Systemic Aspergillosis And Systemic Candidiasis Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
